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reactivity of rheumatoid factor with 
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Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs) are the two most prevalent 
autoantibodies in rheumatoid arthritis (RA), and are thought to have distinct autoantigen targets. 
Whilst RF targets the Fc region of antibodies, ACPAs target a far broader spectrum of citrullinated 
peptides. Here we demonstrate significant sequence and structural homology between proposed RF 
target epitopes in IgG1 Fc and the ACPA target fibrinogen. Two of the three homologous sequences 
were susceptible to citrullination, and this modification, which occurs extensively in RA, permitted 
significant cross-reactivity of RF+ patient sera with fibrinogen in both western blots and ELISAs. 
Crucially, this reactivity was specific to RF as it was absent in RF− patient and healthy control sera, 
and could be inhibited by pre-incubation with IgG1 Fc. These studies establish fibrinogen as a common 
target for both RF and ACPAs, and suggest a new mechanism in RF-mediated autoimmune diseases 
wherein RF may act as a precursor from which the ACPA response evolves.
Rheumatoid Arthritis (RA) is an autoimmune disease characterised by the production of diverse autoantibod-
ies, of which rheumatoid factor (RF) represents a hallmark of the disease, being detectable in up to 80% of RA 
patients1. RF is known to target the Fc region of IgG1 antibodies, forming large immune complexes in syno-
vial tissue2. These deposits initiate localised inflammatory processes and are propagated by the development of 
ectopic secondary lymphoid structures within the joint in which RF undergoes affinity maturation and isotype 
switching3.
The second major group of autoantibodies present in around 60–70% of RA patient sera consti-
tute anti-citrullinated protein antibodies (ACPAs)4. These antibodies target epitopes that have been 
post-translationally modified by the deimination of arginine residues to citrulline. This modification is known to 
occur at a high frequency in RA synovium, as the peptidyl arginine deiminase (PAD) 2 and 4 isoforms responsible 
are overexpressed at this site. The resultant conformational changes produce neo-epitopes representing autoanti-
gens to which tolerance has not been established5,6. Numerous ACPA targets have been identified to date, includ-
ing fibrinogen, filaggrin, vimentin, type II collagen and α-enolase7,8. The recognition of multiple citrullinated 
autoantigens suggests that ACPAs play a crucial role in sustaining the autoimmune response in RA via epitope 
spreading and cross-reactivity9,10. Therapeutic targetting of the initiation of ACPA responses would therefore be 
highly desirable, as it could limit or help resolve RA responses, and could be utilised in other diseases in which 
ACPAs are known to play a role, such as psoriatic arthritis11 and pulmonary tuberculosis12. However, precisely 
how the autoantibody response to citrullinated antigens is initiated and propagated remains unclear.
In this study, we identify regions of sequence homology between the primary target of RF (IgG1 Fc), and 
the ACPA target, fibrinogen13–17, through in silico analysis. As arginine residues were present in the majority 
of these sequences, we utilized novel 3D modelling of citrullination to demonstrate significant sequence and 
structural homology between these regions. Finally, using sera from RA patients stratified based on ACPA and 
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RF titres, we show that RF+ sera readily cross-reacts with fibrinogen after citrullination. These data suggest that 
cross-reactivity of RF with citrullinated auto-antigens represents a novel route for the initiation/propagation of 
ACPA responses in RA, a finding with potential relevance across a spectrum of autoimmune diseases in which RF 
is known to play a role, such as Sjögren’s syndrome and lupus.
Results
Sequence and structural homology between predicted RF epitopes in IgG1 Fc and the ACPA 
target fibrinogen. To determine whether cross reactivity of RF might play an important role in rheumatoid 
pathology, we searched for regions of homology between the sequences of IgG1 Fc (accession no. AF150959.1) 
and those of the fibrinogen β and γ chains (accession nos. P02675 and P02679, respectively) using ExPASy SIM 
and LALIGN software. These searches identified 3 regions of significant sequence homology, with molecular 
modelling using PyMOL further demonstrating significant conformational homology (Fig. 1a). Interestingly, we 
have previously identified 1 of these regions in IgG1 Fc (KPREE) to be a potential major RF-reactive site18. Of 
these 3 regions, 2 contained aligned arginine residues in the sequences of both IgG1 Fc and fibrinogen, identifying 
them as targets for citrullination. Modelling of citrullination of these sequences using the PyTMs plugin did not 
result in the loss of conformational homology (Fig. 1b). Further modelling of the full IgG1 Fc sequence deter-
mined that all 3 of the identified regions would be accessible to RF antibodies (Fig. 1c).
citrullination facilitates cross-reactivity of Rf+ serum with fibrinogen in the absence of 
AcpAs. To determine whether homology between IgG1 Fc and fibrinogen in both their native and citrulli-
nated forms would allow for cross reactivity of RF, we aimed to isolate RF+ sera from RA patients that had no 
detectable ACPAs, so that reactivity of sera samples with citrullinated fibrinogen could be specifically attributed to 
RF. We therefore recruited 42 RA patients (Fig. 2a) and determined their RF and ACPA titres by ELISA (Fig. 2b,c). 
Based on these data, sera were stratified into samples containing ACPAs and RF (ACPA + RF+), ACPAs alone 
(ACPA + RF−), RF alone (ACPA − RF+), or neither antibody (ACPA − RF−). Fibrinogen was then citrullinated 
using a PAD enzyme cocktail (confirmed using a citrulline-specific chemical probe in Fig. 3a), and assessed for 
reactivity with these sera subtypes by western blot. As expected, sera containing ACPAs reacted strongly with 
citrullinated fibrinogen (Fig. 3b, top panel). Despite the significant sequence and structural homology between 
Figure 1. Regions of homology between predicted RF epitopes in IgG1 Fc and fibrinogen are targets for 
citrullination. (a) Three dimensional structures of regions of homology between IgG1 Fc and fibrinogen 
generated using PyMOL software. Sequences were scanned for regions of alignment using ExPASy SIM and 
LALIGN. Numerals indicate amino acid starting position and bold characters indicate amino acid substitutions. 
Characters highlighted in red identify arginine residues susceptible to citrullination. (b) Structures of regions 
of homology identified in (a) after modification of arginine residues to citrulline using PyTMs plugin. (c) 
Structure of the Fc region of IgG1 with the three predicted RF epitopes highlighted: KPREE (green), KSRW 
(cyan), and DELTK (magenta).
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IgG1 Fc and fibrinogen observed in Fig. 1, no detectable reactivity was observed for sera containing RF alone with 
native fibrinogen (Fig. 3b, second panel). However, when fibrinogen was citrullinated we observed binding of RF+ 
sera, even in the absence of detectable ACPAs, suggesting that citrullination facilitates cross-reactivity of RF with 
fibrinogen (Fig. 3b, second panel). This effect was RF-dependent, as reactivity with citrullinated fibrinogen was 
abolished in RF− sera from ACPA− RA patients (Fig. 3b, third panel) or healthy controls (Fig. 3b, bottom panel).
We next sought to confirm these data using ELISAs coated with fibrinogen or IgG1 Fc in their native or citrul-
linated forms. As expected, sera containing RF alone was able to react with native IgG1 Fc, whilst sera containing 
ACPAs alone only reacted with citrullinated IgG1 Fc (Fig. 3c). Accordingly, no reactivity with citrullinated IgG1 
Fc was observed in the absence of ACPAs in RF− sera (Fig. 3c). In agreement with our western blot data, we 
observed limited reactivity of sera containing RF alone with native fibrinogen compared with RF− sera, whilst 
citrullination facilitated a significant increase in RF+ sera reactivity in the absence of ACPAs (Fig. 3d). Consistent 
with this effect being RF-dependent, reactivity with citrullinated fibrinogen was again abolished in RF− sera from 
ACPA− RA patients or healthy controls (Fig. 3d). Moreover, pre-incubation of ACPA-RF+ sera with the RF tar-
get IgG1 Fc significantly inhibited reactivity with citrullinated fibrinogen (Fig. 3e). No IgG was detectable in our 
citrullinated fibrinogen samples, excluding the possibility that contamination was responsible for the reactivity 
observed (Fig. S1). Collectively, these data provide direct evidence that RF is able to cross-react with the ACPA 
target fibrinogen, and that this reactivity is critically dependent on citrullination.
RF reacts with citrullinated fibrinogen in the presence of ACPAs. In Fig. 1a, we identified the homol-
ogous sequences 132-DELTK and 128-DELNN in the IgG1 Fc and fibrinogen peptides, respectively. Because 
these sequences do not contain arginine residues, they are not susceptible to citrullination, and are not targeted 
by ACPAs. This suggests that when the full-length peptides are citrullinated, there remain free epitopes even in 
the presence of ACPAs to which RF may be reactive. To assess this, we established sequential ELISAs coated with 
citrullinated IgG1 Fc or fibrinogen that were first incubated with sera containing ACPAs alone, and then incu-
bated with sera containing either antibody. For both citrullinated IgG1 Fc and fibrinogen, sequential incubation 
with ACPA + sera followed by RF+ sera lead to significantly higher reactivity than was observed with RF− sera 
(Fig. 4a,b). However, sequential incubation with primary ACPAs and secondary RF in this manner could result in 
the binding of RF to the Fc region of ACPA antibodies, which could be responsible for the increase in reactivity 
observed. To address this possibility, we repeated these experiments using ACPA + sera in the primary step that 
had been digested with pepsin to cleave Fc regions and affinity purified to isolate ACPA F(ab’)2 fragments (purity 
confirmed in Fig. S3). In these experiments, sequential incubation with ACPA F(ab’)2 + sera and sera containing 
ACPAs lead to no significant increase in reactivity, suggesting that all free ACPA target epitopes were saturated in 
the primary step (Fig. 4c,d). However, when sera containing RF were used in the secondary step there remained 
Figure 2. Stratification of rheumatoid arthritis patients according to serum titres of RF and ACPAs. (a) Patient 
characteristics amongst the four sera sub-types. (b) RF titres determined by IgG1 Fc-based ELISA for the four 
sera sub-types. Threshold for RF+ was set at 20 U/mL (red line). (c) ACPA titres determined by citrullinated 
protein-based ELISA for the four sera sub-types. Threshold for ACPA+ was set at 5 U/mL (red line).
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a significant increase in reactivity for both IgG1 Fc and fibrinogen (Fig. 4c,d). For fibrinogen, these data suggest 
that RF is able to interact with citrullinated fibrinogen even when in competition with ACPAs, by targeting addi-
tional non-ACPA target epitopes.
Discussion
In this study, we utilised RF+ sera from RA patients seronegative for ACPAs to assess the ability of RF to react 
with citrullinated ACPA target proteins. Although these sera are composed of a heterogeneous mix of autoanti-
bodies in addition to those assessed here, binding of ACPA- sera to citrullinated fibrinogen was only observed 
in RF+ samples, and this binding could be inhibited using the RF target IgG1 Fc, suggesting RF is the major 
determinant of reactivity. Previous studies have shown that only 4–8% of ACPA- RA sera react with the fibrino-
gen β chain when a single arginine residue is citrullinated4. Our data suggest that citrullination at multiple sites 
is therefore necessary to elicit reactivity with RF. It has been reported that citrullination can improve protein 
immunogenicity as a result of steric shifts and effects on relaxation dynamics in citrullinated proteins6. This find-
ing is also in agreement with observations made by Hill and colleagues19, which suggest that the RA-associated 
HLA DRB1*0401 has a higher affinity for citrulline-modified peptides than for their native counterparts. These 
Figure 3. Citrullination facilitates cross-reactivity of RF+ serum with fibrinogen in the absence of ACPAs. 
(a) Native fibrinogen and IgG1 Fc were citrullinated in-house using a PAD enzyme cocktail or commercially 
(fibrinogen) and probed using a citrulline-specific reporter (rhodamine-phenylglyoxal). (b) Native or citrullinated 
fibrinogen was probed using sera from the indicated RA patient cohorts or healthy controls. Full length gels are 
shown in Fig. S2. (c) Graph shows serological response to native or citrullinated IgG1 Fc in the indicated RA 
patient cohorts or healthy controls, determined by ELISA. (d) Graph shows serological response to native or 
citrullinated fibrinogen in the indicated RA patient cohorts or healthy controls, determined by ELISA. (e) Graph 
shows reactivity of ACPA-RF+ sera with citrullinated fibrinogen after pre-incubation as indicated, determined by 
inhibition ELISA. Data in (e) represent three independent experiments. ****p < 0.0001; ***p < 0.001.
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observations, alongside the fact that citrullination is a common feature of the rheumatoid joint, may explain why 
we observed more limited reactivity of RF+ RA sera with native fibrinogen, despite its homology with IgG1 Fc.
In recent years, a model for the initiation of rheumatoid pathology has been proposed that suggests ACPAs 
target citrullinated autoantigens, forming immune complexes containing Fc regions that initiate the production 
of RF20. According to this model, RF is dependent on ACPAs and should appear after the ACPA response is ini-
tiated. However, this model does not account for the production of RF in ACPA- patients. Broadening the model 
to include immune complexes containing non-citrullinated antigens reverses this order, with RF generated in 
response to immune complexes resulting in inflammation, influx of PAD enzymes, hypercitrullination and onset 
of the ACPA response20. In this model, ACPAs are therefore generated as an indirect result of the RF response. 
A number of studies have assessed the production of autoantibodies in the years before symptomatic RA, and it 
is clear that both RF and ACPAs can be produced during this period21–26. However, there is no clear consensus 
as to whether either antibody precedes the other, suggesting that both of the above models likely occur to some 
extent. In this study, we have shown that citrullination results in significant cross-reactivity of RF with a classical 
ACPA target, fibrinogen. Crucially, this observation suggests the possibility that RF could act directly as an ACPA 
precursor, blurring the line between what have always been considered distinct antibody classes in RA pathology. 
Therapeutic targeting of RF may therefore represent a route to limiting the ACPA response, which could help 
resolve inflammatory disease in RA and other autoimmune conditions such as lupus and Sjögren’s syndrome.
Methods
patients with rheumatoid arthritis. Peripheral venous blood was collected from 42 Patients with RA 
recruited at Cannock Chase and New Cross NHS Hospitals, United Kingdom. All patients fulfilled the American 
College of Rheumatology criteria for the diagnosis of RA. Control sera (n = 20) were obtained from healthy indi-
viduals. Informed written consent was obtained from all participants and ethical approval was granted by the 
National Research Ethics Committee. All experiments were carried out in accordance with institutional guidelines.
Measurement of Rf and AcpA titres. Serum autoantibody titres were determined using commercial 
ELISA kits to assay RF (Abnova) and ACPAs (EuroDiagnostica) according to the manufacturers’ instructions.
In silico analyses. The sequences of human fibrinogen (accession no. β: P02675, γ: P02679) and IgG1 Fc 
(accession no. AF150959.1) were obtained from the NCBI/GenBank database (www.ncbi.nlm.nih.gov/gquery/). 
Sequences were compared by pairwise BLAST analysis (www.ncbi.nlm.nih.gov/BLAST/) and scanned for regions 
of homology using ExPASy SIM (www.web.expasy.org/sim/) and LALIGN (www.ebi.ac.uk/Tools/psa/lalign/). 
Replacement scores were obtained using a substitution matrix developed by Tűdős et al.27.
Molecular models of homologous regions were created using PyMOL (www.pymol.org/pymol), with citrul-
lination modelling achieved using the PyTMs plugin28. A model of the full human IgG1 Fc (entry: 5JII) was 
obtained from the Protein Data Bank (www.rcsb.org), processed with PyTMs plugin, and enhanced using UCSF 
Chimera (www.cgl.ucsf.edu/chimera).
In vitro citrullination. Native human fibrinogen (Bio-Rad) and IgG1 Fc (Abcam) were citrullinated by 3 h 
incubation at 55 °C with active PAD enzyme cocktail (0.5 µg/µL; P312-37C-25; SignalChem). Native control 
samples were prepared using the same protocol, in the absence of enzymes. Commercially citrullinated human 
fibrinogen (CAY400076; Cambridge Bioscience) was used as a positive control. Citrullination was confirmed by 
labelling with rhodamine-phenylglyoxal (Cayman Chemical) according to the protocol described in Bicker et 
al.29, and imaging.
Figure 4. RF reacts with citrullinated fibrinogen in the presence of ACPAs. Graphs show serological response 
to citrullinated IgG1 Fc (a) or fibrinogen (b) when incubated with ACPA + sera (step 1), followed by incubation 
with the indicated RA patient sera-subtypes (step 2), determined by sequential ELISA. The same experiments 
were repeated using ACPA + sera digested with pepsin in step 1 (dACPA + RF−) for citrullinated IgG1 Fc (c) 
or fibrinogen (d). Data represent three independent experiments. ****p < 0.0001; ***p < 0.001; **p < 0.01; 
*p < 0.05.
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Gel electrophoresis and Western blot. Protein samples in loading buffer were heated at 96 °C for 30 min, 
separated on a 6% SDS-PAGE, and transferred onto nitrocellulose by electroblotting. Membranes were blocked 
with 5% milk powder for 1 hr before probing with patient serum samples (1/200) overnight at 4 °C. Bands were 
visualized by incubation with HRP-labelled goat F(ab’)2 anti-human IgG conjugate (STAR97P; Serotec) for 1 hr, 
followed by enhanced chemiluminescence detection system (Amersham), and imaging.
ELISA. Screening of fibrinogen and IgG1 Fc was conducted as previously described30. Briefly, proteins were 
coated (8 µg/mL) onto 96-well multiscreen plates (2 HB Immulon; Dynex) and incubated overnight at 4 °C. Plates 
were blocked with 2% BSA for 1 h at 37 °C. Sera were then used alone or sequentially (1/200; 1 hr), as indicated, 
followed by incubation with HRP-labelled F(ab’)2 anti-human IgG conjugate (6 µg/mL; 1 hr), and TMB (Sigma 
Aldrich) before reading at 450 nm. For inhibition assays sera were pre-incubated alone, with myelin (Sigma 
Aldrich; 10 µg/mL) or IgG1 Fc (10 µg/mL) for 1 hr at 37 °C.
Antibody digestion with pepsin. ACPA + RF− sera were incubated with active pepsin (Sigma Aldrich) 
at a 20:1 ratio (serum:enzyme) for 1 hr at 37 °C. F(ab’)2 fragments were negatively selected using Protein G affin-
ity columns (Thermo Fisher) and filtered over a 30 kDa membrane (Millipore) to remove low molecular weight 
contaminants.
Statistical analyses. Results are presented as mean and SEM. Unpaired t tests with a 95% confidence inter-
val were used for pairwise comparisons to determine statistical significance.
Data Availability
The datasets generated during the current study are available from the corresponding author on reasonable re-
quest.
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